USPTO serial 79430723
CLOCK.BIO
Reviewed by CopyMark Law Group
Status 645Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- PARKS, KIMBERLY L
- Law office
- TMO LAW OFFICE 112
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with CLOCK.BIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | Non-medicated cosmetics and toiletry preparations; cosmetics and cosmetic preparations; skin care preparations, not for medical purposes. | ACTIVE | — |
| 005 | Cell therapeutics for medical, pharmaceutical, clinical and veterinary use; genetically or otherwise modified cells for medical, medical diagnostic, pharmaceutical, clinical and veterinary use; cells which are propagated, cultivated and expanded in bioreactors, all being for medical, medical diagnostic, pharmaceutical, clinical and veterinary use; cells for the purpose of tissue regeneration, all being for medical, pharmaceutical, clinical and veterinary use; living cells for medical use; cells for medical use; biological preparations for medical use for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, renal, oncological, hepatological, hematological, ophthalmic, respiratory, neurological, gastrointestinal, genitourinary, hormonal, dermatological, infectious, and immune system related diseases and disorders; diagnostic preparations for medical and veterinary purposes; pharmaceutical cell preparations for drug screening; pharmaceutical cell preparations for genetic testing and screening; stem cells for medical purposes; stem cells for veterinary purposes; cell growth media for growing cells for medical, pharmaceutical, clinical and veterinary, and diagnostic use; tissue culture media for use in tissue culture for medical, pharmaceutical, clinical and veterinary, and diagnostic use; cytokines, antibodies, and reagents for medical, medical research and diagnostic use; tissue culture media, growth factors, growth media, serum, and nutritional supplements for in vitro culturing, development, maintenance, expansion, assay and manipulation of cells; cell separation reagents for medical, medical diagnostic, pharmaceutical, clinical and veterinary purposes; dietary supplements; protein supplements; nutrition supplements. | ACTIVE | — |
| 040 | Custom manufacture of biopharmaceuticals; custom manufacture of stem cells for research purposes, stem cells for scientific purposes, stem cells other than for medical or veterinary purposes, skeletal myocytes for research purposes, cortical neurons for research purposes, biological tissue for research and scientific purposes, biological tissue cultures other than for medical or veterinary purposes, cultures of cell media, chemical reagents for use in biotechnology, other than for medical or veterinary use, nutritive agents for processing living cells, semi-processed natural proteins for manufacturing food, proteins for use in the manufacture of food products, proteins for use in recombinant DNA technology, cell therapeutics, genetically or otherwise modified cells, cells which are propagated, cultivated and expanded in bioreactors, cells for the purpose of tissue regeneration, living cells for medical use, cells for medical use, biological preparations for medical use, diagnostic preparations for medical and/or veterinary purposes, cell preparations for drug screening, cell preparations for genetic testing and screening, stem cells for medical purposes, stem cells for veterinary purposes, cell growth media, tissue culture media, cytokines, antibodies, and reagents for medical, medical research or diagnostic use, tissue culture media, growth factors, growth media, serum, and nutritional supplements for in vitro culturing, development, maintenance, expansion, assay or manipulation of cells, cell separation reagents, magnetic cell separation equipment, dietary supplements, protein supplements and nutrition supplements. | ACTIVE | — |
| 042 | Biotechnology research; biotechnology testing for others in the area of biotechnology for research, clinical, therapeutic and manufacturing purposes; stem cell research; synthetic biology services, namely biological research; stem cell biology services, namely biological research and analysis; scientific laboratory services relating to the isolation and cultivation of human tissues and cells; research and development in the field of microorganisms and cells; research and development in relation to genetic testing and screening; research and development in relation to drug screening; cell separation technology services for scientific, research, clinical, medical, and manufacturing purposes; cell separation research services; consultancy relating to biotechnology; consultancy relating to drug screening for scientific research purposes; consultancy relating to genetic screening for scientific research purposes; consultancy relating to cell therapy for scientific research purposes; laboratory research in the field of pharmaceutical and drug discovery; research on food; research and development in the field of animal cells cultivated within bioreactors; research in the reduction of carbon emissions; development and testing of computing methods, algorithms and software for medical, clinical, research and biomanufacturing purposes. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 1, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| May 1, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 1, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 20, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 20, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 20, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 7, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 18, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 18, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 17, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 17, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 17, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 17, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 3, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 2, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 26, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 25, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 25, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 21, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |